Source: Geron Corporation
Posted: November 7, 2007 7:30 am ET
Summary:
In an official company news release, Geron Corporation, a biotechnology company in the field of stem cell research, reported its embryonic stem cell therapy to treat spinal cord injury regenerated parts of spinal cord nerve coating tissue in rats called myelin:
"Geron Corporation today announced that data show GRNOPC1, the company’s human embryonic stem cell (hESC)-based therapeutic for spinal cord injury, survives and exhibits durable and robust human remyelination in spinal cord-injured rats for at least nine months following a single injection. The data also demonstrate that GRNOPC1 does not amplify neuropathic pain or the reaction to painful stimuli. This finding is in contrast to research that shows many other cell types, when injected into the spinal cord, amplify neuropathic pain, a common long-term complication of spinal cord injury in man."
